We are live on ! Find out more
MRVI icon

Maravai LifeSciences

158 hedge funds and large institutions have $344M invested in Maravai LifeSciences in 2026 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 51 increasing their positions, 52 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

19% more call options, than puts

Call options by funds: $1.29M | Put options by funds: $1.08M

17% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 24

1% less funds holding

Funds holding: 159158 (-1)

2% less repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 52

6.28% less ownership

Funds ownership: 89.23%82.95% (-6.3%)

18% less capital invested

Capital invested by funds: $421M → $344M (-$77.2M)

20% less funds holding in top 10

Funds holding in top 10: 54 (-1)

Holders
158
Holders Change
-1
Holders Change %
-0.63%
% of All Funds
1.94%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.05%
New
28
Increased
51
Reduced
52
Closed
24
Calls
$1.29M
Puts
$1.08M
Net Calls
+$207K
Net Calls Change
-$3.15M
Name Holding Trade Value Shares
Change
Change in
Stake
GL
1
GTCR LLC
Illinois
$57M
B
2
Braidwell
Connecticut
$29M +$6.4M +1,886,877 +23%
BlackRock
3
BlackRock
New York
$26.4M -$113K -33,193 -0.4%
1WCM
4
12 West Capital Management
New York
$20.5M -$5.63M -1,661,140 -19%
Mackenzie Financial
5
Mackenzie Financial
Ontario, Canada
$17.8M +$450K +132,769 +2%
VCM
6
Vanguard Capital Management
Pennsylvania
$15.4M +$18.5M +5,449,702 New
Renaissance Technologies
7
Renaissance Technologies
New York
$12.1M +$134K +39,600 +0.9%
TC
8
Tejara Capital
United Kingdom
$9.89M +$1.61M +474,978 +16%
MAM
9
Monaco Asset Management
Monaco
$9.68M -$133K -39,170 -1%
Morgan Stanley
10
Morgan Stanley
New York
$9.39M -$432K -127,477 -4%
Point72 Asset Management
11
Point72 Asset Management
Connecticut
$9.07M +$1.21M +357,697 +13%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$8.01M -$66.1K -19,510 -0.7%
PCM
13
Philosophy Capital Management
California
$7.46M -$1.57M -463,205 -15%
First Eagle Investment Management
14
First Eagle Investment Management
New York
$7.14M +$2.46M +725,000 +40%
State Street
15
State Street
Massachusetts
$6.87M +$49.1K +14,468 +0.6%
Marshall Wace
16
Marshall Wace
United Kingdom
$5.89M +$275K +81,056 +4%
Goldman Sachs
17
Goldman Sachs
New York
$5.72M +$20.7K +6,115 +0.3%
RA
18
Royce & Associates
New York
$5.12M +$347K +102,299 +6%
GAI
19
General American Investors
New York
$4.86M +$444K +130,877 +8%
Millennium Management
20
Millennium Management
New York
$4.67M -$500K -147,562 -8%
Jane Street
21
Jane Street
New York
$4.63M +$1.16M +341,087 +26%
Two Sigma Investments
22
Two Sigma Investments
New York
$4.47M +$2.49M +734,432 +87%
SFM
23
Systematic Financial Management
New Jersey
$4.2M -$121K -35,781 -2%
Citadel Advisors
24
Citadel Advisors
Florida
$4.2M +$2.94M +866,865 +140%
Dimensional Fund Advisors
25
Dimensional Fund Advisors
Texas
$4.02M +$1.89M +558,050 +65%

MRVI Hedge Fund Activity: Q1 2026 in Review

158 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Maravai LifeSciences (MRVI) for Q1 2026, worth a combined $344M — down 18% from $421M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new MRVI positions and 24 closed out — a net gain of 4 holders — while 51 added to existing stakes and 52 trimmed.

The largest buyer was Braidwell, adding an estimated $6.4M. The largest seller was T. Rowe Price Investment Management, cutting an estimated $18.1M.

  • 158 institutional investors held Maravai LifeSciences (MRVI) as of Q1 2026, down from 159 in Q4 2025.
  • Funds reported $344M of Maravai LifeSciences stock for Q1 2026, down 18% quarter-over-quarter.
  • 28 funds opened new Maravai LifeSciences positions in Q1 2026 and 24 closed out, a net change of +4 holders.
  • The largest Maravai LifeSciences buyer in Q1 2026 was Braidwell, an estimated $6.4M added.
  • The largest Maravai LifeSciences seller in Q1 2026 was T. Rowe Price Investment Management, an estimated $18.1M sold.

Based on aggregated 13F filings for Q1 2026.